• About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Disease Focus

We are focused on the development of a next-generation drug to benefit the millions of people suffering from dry eye disease and other inflammatory diseases of the eye. Our immediate goal is to overcome the limitations of current dry eye treatments with the development of a first-in-class drug that combines both anti-inflammatory and pain reducing activity.

Innovative Approach for Inflammatory Eye Diseases

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

© OKYO Pharma, Limited | 2023

Explore

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Follow

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Legal

  • Legal
  • Privacy Policy
MENU
  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact